Regeneron (REGN) Surges On Strong Initial Eylea Uptake
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $826.64 -1.69%
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Research and development: 543.05M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) is surging nearly 15 percent in pre-open action Tuesday after solid Eylea guidance at the JPMorgan conference.
The firm said while the they are still early in the launch, the initial uptake has exceeded expectations. The company noted $24-$25 million in unaudited net sales to distributors in 2011 since the first sale on November 21, 2011.
Following the conference and guidance, RW Baird upgraded the stock to Outperform with an $81 price target saying it's not too late to get in.
The firm said while the they are still early in the launch, the initial uptake has exceeded expectations. The company noted $24-$25 million in unaudited net sales to distributors in 2011 since the first sale on November 21, 2011.
Following the conference and guidance, RW Baird upgraded the stock to Outperform with an $81 price target saying it's not too late to get in.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
Create E-mail Alert Related Categories
Guidance, Trader TalkRelated Entities
JPMorgan, Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
